Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
Liver Physiology01:30

Liver Physiology

The liver, an essential organ in the human body, performs over 200 vital functions that can be broadly categorized into metabolic, hematological, endocrine regulation, and bile production.
Metabolic Regulation:
The liver is the central organ involved in regulating blood composition. It stabilizes blood glucose levels, maintaining them within the range of  70–110 mg/dL. When these levels drop, the liver breaks down glycogen reserves and releases glucose into the bloodstream. It can also...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Weight change and long-term cardiovascular outcomes in overweight and obese patients after acute coronary syndromes.

European heart journal open·2026
Same author

Does HDL-C matter when predicting risk of cardiovascular disease in older people with type 2 diabetes?

European journal of preventive cardiology·2026
Same author

Safety of low lipoprotein(a) levels: the FOURIER trial.

European heart journal·2026
Same author

Practical Recommendations for Anticoagulation in Patients With Atrial Fibrillation.

European journal of clinical investigation·2026
Same author

Impact of aetiology and liver stiffness on thrombin generation in compensated cirrhosis.

Thrombosis research·2026
Same author

Thyroid dysfunction and cardiovascular disease.

European heart journal·2026
Same journal

Revue medicale suisse·2026
Same journal

Revue medicale suisse·2026
Same journal

Revue medicale suisse·2026
Same journal

Revue medicale suisse·2026
Same journal

Revue medicale suisse·2026
Same journal

[Erythema multiforme : target deciphering].

Revue medicale suisse·2026
See all related articles

Related Experiment Video

Updated: May 23, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

[Lipid-lowering treatment and liver dysfunction].

Baris Gencer1, Darius Moradpour, Nicolas Rodondi

  • 1Service de gastro-entérologie et d'hépatologie, Département de médecine, CHUV, 1011 Lausanne. baris.gencer@chuv.ch

Revue Medicale Suisse
|April 5, 2012
PubMed
Summary
This summary is machine-generated.

Statins are generally safe for cardiovascular prevention but can cause reversible liver enzyme elevations. Caution is advised in patients with chronic liver disease, with contraindications including decompensated cirrhosis.

Related Experiment Videos

Last Updated: May 23, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Area of Science:

  • Pharmacology
  • Hepatology
  • Cardiovascular Medicine

Context:

  • Statins are widely prescribed for cardiovascular disease prevention.
  • Hepatic adverse effects, primarily elevated liver enzymes, are the most common concern.
  • Understanding statin safety in patients with pre-existing liver conditions is crucial.

Purpose:

  • To review the hepatic safety profile of statins.
  • To clarify the use of statins in patients with chronic liver diseases.
  • To provide guidance on monitoring and managing statin-induced liver enzyme elevations.

Summary:

  • Statins are generally well-tolerated, with asymptomatic, reversible liver enzyme increases being the main hepatic side effect.
  • Statins can be cautiously used in most patients with chronic liver diseases like NAFLD and hepatitis C.
  • Decompensated cirrhosis and acute liver failure are contraindications; routine monitoring is debated, but ALT elevation >3x ULN warrants investigation and potential cessation.

Impact:

  • Informs clinical practice regarding statin use in diverse patient populations.
  • Reduces unnecessary monitoring while ensuring appropriate caution in high-risk individuals.
  • Contributes to the safe and effective utilization of statins in cardiovascular prevention.